Preliminary financial results for 2025:
HARTMANN increases sales and earnings once again

Heidenheim, 3 February 2026. The HARTMANN GROUP achieved preliminary organic sales growth of 2.2% in the 2025 financial year.

At EUR 277 million, preliminary adjusted EBITDA is around EUR 15 million higher than in the previous year. This also represents an improvement in the margin range of 0.3%. The company's Transformation Program once again made a significant contribution to earnings.

“HARTMANN was able to increase its sales revenues and profitability despite a decline in key core markets. We are succeeding in winning through new product launches and cost measures, as well as through new customer-oriented solutions. We will therefore continue to invest in strategic target markets,” says Britta Fünfstück, CEO of the HARTMANN GROUP.

A progressive forecast for 2026 will be published on 19 March 2026, when the full financial results for 2025 are released.

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e.g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” Founded in 1818, the Company sells its products and solutions in 130 countries around the world.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.